Skip to main content

Rosenwald Lindsay A MD's Form 4 filing

Fortress Biotech, Inc.FBIO · filed Jul 15, 2024

Accession no.
0001104659-24-079855
Filed
Jul 15, 2024
Trade date
Jul 11, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market purchases total $37.4K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Rosenwald Lindsay A MDCIK 0000941841Director, Officer (President, CEO & Chairman), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 11, 2024SERIES A CUMULATIVE PERPETUAL PREFERRED STOCKPPurchaseAcquired+5,000$7.48F1+$37,400127,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 11, 2024 was $7.35 to $7.49. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)